Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Aeovian Pharmaceuticals logo — company profile

Aeovian Pharmaceuticals

United States Berkeley, United States 10 employees

General Information

Company Name Aeovian Pharmaceuticals
Location United States Berkeley, United States +1
Employees 10
Social

Get notified when Aeovian Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Aeovian Pharmaceuticals

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS penetrant selective mTORC1 inhibitor being developed for the treatment of TSC refractory epilepsy and is currently being evaluated in a Phase 1 trial. TSC is a rare genetic disorder caused by the hyperactive signaling of mTORC1. Beyond AV078, we’ve developed a proprietary library of small molecules, which are potent and selective mTORC1 and CD38 inhibitors that have the potential to precisely target the underlying biology of multiple rare and age-related disease

No funding data available for Aeovian Pharmaceuticals yet.

Get notified when Aeovian Pharmaceuticals raises funding

Aeovian Pharmaceuticals Alternatives & Competitors

Aeovian Pharmaceuticals vs
Imara
Imara

Pioneering therapeutic advancements with innovative solutions for rare genetic hemoglobin disorders.

Post Ipo Equity
11-50 employees
Biopharma, Biotechnology
Aeovian Pharmaceuticals vs
Allinky Biopharma
Allinky Biopharma

Among the therapeutic areas of partnering interest, for the top pharmaceutical companies, oncology,...

3 employees
Biotechnology, Health Care
Aeovian Pharmaceuticals vs
Dice Therapeutics
Dice Therapeutics

Pioneering oral solutions to combat chronic diseases in immunology with innovative selective small m...

Post Ipo Equity
Biotechnology, Medical Devices

FAQ About Aeovian Pharmaceuticals

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases....
Aeovian Pharmaceuticals is headquartered in Berkeley, United States.
Aeovian Pharmaceuticals has approximately 10 employees.
Top alternatives and competitors to Aeovian Pharmaceuticals include Imara, Allinky Biopharma, Dice Therapeutics, Biomea Fusion, ONL Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aeovian Pharmaceuticals and Imara are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Aeovian Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes